Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

109 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Studies on the red marrow dosimetry in radioimmunotherapy: an experimental investigation of factors influencing the radiation-induced myelotoxicity in therapy with beta-, Auger/conversion electron-, or alpha-emitters.
Behr TM, Sgouros G, Stabin MG, Béhé M, Angerstein C, Blumenthal RD, Apostolidis C, Molinet R, Sharkey RM, Koch L, Goldenberg DM, Becker W. Behr TM, et al. Among authors: apostolidis c. Clin Cancer Res. 1999 Oct;5(10 Suppl):3031s-3043s. Clin Cancer Res. 1999. PMID: 10541340
High-linear energy transfer (LET) alpha versus low-LET beta emitters in radioimmunotherapy of solid tumors: therapeutic efficacy and dose-limiting toxicity of 213Bi- versus 90Y-labeled CO17-1A Fab' fragments in a human colonic cancer model.
Behr TM, Béhé M, Stabin MG, Wehrmann E, Apostolidis C, Molinet R, Strutz F, Fayyazi A, Wieland E, Gratz S, Koch L, Goldenberg DM, Becker W. Behr TM, et al. Among authors: apostolidis c. Cancer Res. 1999 Jun 1;59(11):2635-43. Cancer Res. 1999. PMID: 10363986
Validation of 213Bi-alpha radioimmunotherapy for multiple myeloma.
Couturier O, Faivre-Chauvet A, Filippovich IV, Thédrez P, Saï-Maurel C, Bardiès M, Mishra AK, Gauvrit M, Blain G, Apostolidis C, Molinet R, Abbe JC, Bataille R, Wijdenes J, Chatal JF, Chérel M. Couturier O, et al. Among authors: apostolidis c. Clin Cancer Res. 1999 Oct;5(10 Suppl):3165s-3170s. Clin Cancer Res. 1999. PMID: 10541359
Cyclotron production of Ac-225 for targeted alpha therapy.
Apostolidis C, Molinet R, McGinley J, Abbas K, Möllenbeck J, Morgenstern A. Apostolidis C, et al. Appl Radiat Isot. 2005 Mar;62(3):383-7. doi: 10.1016/j.apradiso.2004.06.013. Appl Radiat Isot. 2005. PMID: 15607913
Alpha-emitting bismuth cyclohexylbenzyl DTPA constructs of recombinant humanized anti-CD33 antibodies: pharmacokinetics, bioactivity, toxicity and chemistry.
Nikula TK, McDevitt MR, Finn RD, Wu C, Kozak RW, Garmestani K, Brechbiel MW, Curcio MJ, Pippin CG, Tiffany-Jones L, Geerlings MW Sr, Apostolidis C, Molinet R, Geerlings MW Jr, Gansow OA, Scheinberg DA. Nikula TK, et al. Among authors: apostolidis c. J Nucl Med. 1999 Jan;40(1):166-76. J Nucl Med. 1999. PMID: 9935073 Free article.
Cytotoxicity of 213Bi- and 225Ac-immunoconjugates.
Kaspersen FM, Bos E, Doornmalen AV, Geerlings MW, Apostolidis C, Molinet R. Kaspersen FM, et al. Among authors: apostolidis c. Nucl Med Commun. 1995 Jun;16(6):468-76. doi: 10.1097/00006231-199506000-00009. Nucl Med Commun. 1995. PMID: 7675360
109 results